BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Rhea-AI Summary
BeyondSpring (NASDAQ:BYSI) reported updated Phase 2 data for pembrolizumab plus plinabulin/docetaxel in metastatic NSCLC patients progressing after first-line immune checkpoint inhibitors.
Among 47 patients, median PFS was 7.0 months, median DoR 9.3 months, DCR 79.5%, ORR 18.2%, and 12‑/24‑month OS rates 78.1% and 58.0%, with manageable safety.
AI-generated analysis. Not financial advice.
Positive
- Median PFS 7.0 months in post-ICI metastatic NSCLC
- Disease control rate of 79.5% (PR + SD > 4 months)
- Median duration of response of 9.3 months
- Confirmed objective response rate of 18.2%
- 12‑month OS 78.1% and 24‑month OS 58.0%; median OS not reached
Negative
- 53.2% of patients had grade 3 or higher treatment-related adverse events
- Grade 3+ hypertension and neutrophil decrease each occurred in 17.0% of patients
News Market Reaction – BYSI
On the day this news was published, BYSI declined 2.30%, reflecting a moderate negative market reaction. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $71.55M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BYSI gained 3.57% while peers were mixed: IMMX up 4.77%, OSTX down 12.62%, ACET down 4.83%, ALGS down 6.14%, IGMS down 2.31%. Moves do not indicate a unified biotech rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Phase 3 subset data | Positive | -3.2% | ESMO Asia DUBLIN-3 Asian subset showed OS and safety benefits vs docetaxel. |
| Dec 11 | Post-ICI analysis | Positive | +7.9% | NACLC 2025 DUBLIN-3 analyses showed better survival and brain metastasis outcomes. |
| Jul 07 | ICI-failure study | Positive | +1.8% | Med (Cell Press) study showed DC maturation and responses after checkpoint failure. |
| Jun 03 | Phase 2 303 update | Positive | +4.3% | ASCO 2025 Phase 2 303 data showed improved PFS, DCR and ORR in post-ICI NSCLC. |
| Nov 11 | Triple IO combo data | Positive | +2.1% | SITC 2024 Phase 2 triple combo data showed high DCR and durable responses. |
Clinical trial updates for plinabulin have usually been followed by positive share moves, though there has been at least one notable negative reaction despite favorable data.
Over the past year, BeyondSpring has repeatedly highlighted clinical progress for plinabulin in NSCLC and other settings. Events at SITC, ASCO, NACLC, and ESMO Asia showed improved survival, progression-free survival, and response rates when plinabulin was added to docetaxel or checkpoint inhibitors. Same-tag clinical updates on 2024-11-11, 2025-06-03, 2025-07-07, 2025-12-11, and 2025-12-12 generally led to share gains, framing today’s ASCO 2026 Phase 2 update as part of an ongoing efficacy story in post-ICI NSCLC.
Historical Comparison
In the past five clinical trial updates, BYSI moved an average of 2.57%, typically reacting positively to plinabulin efficacy data. Today’s ASCO 2026 Phase 2 results extend that same NSCLC, post-ICI narrative.
Clinical news traces a progression from early triple-combo Phase 2 data in metastatic NSCLC through larger Phase 3 DUBLIN-3 analyses and multiple post-ICI subsets, with recurring themes of improved survival, disease control, and reduced neutropenia when plinabulin is added.
Market Pulse Summary
This announcement reports updated Phase 2 data in metastatic NSCLC after progression on first-line immune checkpoint inhibitors, with improved PFS, DoR, DCR, and survival rates versus historical docetaxel data. Prior clinical updates on plinabulin, including DUBLIN-3 analyses and earlier 303 results, similarly emphasized survival and safety benefits. Investors may watch for larger, confirmatory studies, regulatory feedback, and how these efficacy findings integrate with the company’s recent financial and SEC disclosures.
Key Terms
progression-free survival medical
duration of response medical
disease control rate medical
objective response rate medical
overall survival medical
non-small cell lung cancer medical
immune checkpoint inhibitor medical
GEF-H1 agonist medical
AI-generated analysis. Not financial advice.
- Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of
79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitors - Durable survival benefit: 12-month OS rate of
78.1% and 24-month OS rate of58.0% in a patient population with limited treatment options - Good tolerability and immune activation: Along with increased frequencies of activated CD4+/CD8+ T cells post-treatment, hematology test also showed safety benefit with significantly higher levels of WBCs, neutrophils and platelets.
FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced updated efficacy and safety data from the investigator-initiated Phase 2 303 Study evaluating pembrolizumab plus Plinabulin and docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) after progression on first-line immune checkpoint inhibitor (“ICI”) therapy, either alone or in combination with chemotherapy. The data were presented at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting by Dr. Mengzhao Wang and Dr. Yan Xu, principal investigators from Peking Union Hospital.
First-in-class small molecule agent Plinabulin is a brain-penetrant, uniquely reversible tubulin binder with immunomodulatory properties that promote dendritic cell maturation, M1 polarization and anti-tumor T-cell responses. As a GEF-H1 agonist, Plinabulin is designed to strengthen the cancer-immunity cycle, support immune activation, and help address chemotherapy-induced neutropenia, providing a potential differentiated approach in the post-ICI treatment setting.
The open-label Phase 2 study enrolled 47 patients with metastatic NSCLC who had progressed following prior ICI therapy, including 6 patients previously treated with ICI alone and 41 patients previously treated with ICI plus platinum-doublet chemotherapy. All patients had secondary resistance, defined as prior ICI treatment with progression-free survival of at least six months. Pembrolizumab (200 mg), Plinabulin (30 mg/m2) and docetaxel (75 mg/m2) were all dosed intravenously on day 1 of a 21-day cycle.
As of the February 28, 2026 data cutoff, the median follow-up was 28.8 months. Three patients remained on treatment, and 24 patients remained alive in survival follow-up. Among the 47 enrolled patients, the median age was 67 years;
- Median Progression-Free Survival (PFS): 7.0 months — compared favorably with historical docetaxel data in similar post-ICI patient populations, including TROPION-Lung01 and EVOKE-01, which reported median PFS of 3.7 months and 3.9 months, respectively
- Median Duration of Response (DoR): 9.3 months – indicating durable response
- Disease Control Rate (DCR: PR + SD > 4 months):
79.5% — indicating clinical benefit in the majority of patients who progressed on prior PD-1/L1 inhibitor-based therapy - Confirmed Objective Response Rate (ORR):
18.2% — compared favorably with historical 5-12% ORR for docetaxel, demonstrating anti-tumor activity in metastatic NSCLC patients with secondary resistance to prior ICI - 12-Month Overall Survival (OS) Rate:
78.1% ; 24-Month OS Rate:58.0% , with median OS not reached — compared favorably with historical docetaxel data in similar patient populations, including TROPION-Lung01 and EVOKE-01, which reported median OS of 11.8 months and 9.8 months, respectively - The combination demonstrated a generally manageable safety profile.
53.2% of patients experienced grade 3 or higher treatment-related adverse events, including hypertension in17.0% , gastrointestinal disorders in14.9% , neutrophil decrease in17.0% , decreased white blood cell count in6.4% , and febrile neutropenia in2.1%
“These updates continue to support Plinabulin’s potential to address one of the most significant unmet needs in lung cancer: treatment options for patients whose disease has progressed after ICI therapy,” said Dr. Mengzhao Wang, principal investigator from Peking Union Hospital in China. “With 24-month OS rate of
BeyondSpring’s ASCO 2026 Presentation
- Title: A Phase 2 Study of Plinabulin (Plin)/Docetaxel (Doc) plus Pembrolizumab (Pemb) in Metastatic NSCLC (mNSCLC) After Acquired Resistance (AR) to Anti-PD-1/L1 Alone or in Chemotherapy Combination: Efficacy and Immunophenotyping
- Presenter/Authors: Yan Xu, Minjiang Chen, Xiaoxing Gao, Huiyu Huang, Yue Chang, Xiaoyan Liu, Wei Zhong, Jing Zhao, RuiLi Pan, Taisheng Li, Mengzhao Wang
- Session: Lung Cancer – Non-Small Cell Metastatic (Track)
- Abstract Number: 8567
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Plinabulin’s novel mechanism as a GEF-H1 agonist with dendritic cell maturation benefit supports both anti-cancer activity and immune modulation, offering a unique approach to re-sensitizing tumors resistant to checkpoint inhibitors. In addition, it has the potential to synergize with chemotherapy, antibody drug conjugates (ADC), radiation, and checkpoint inhibitors. Learn more at beyondspringpharma.com.
About the 303 Study
The 303 Study is an open-label, single-arm Phase 2 study of Plinabulin plus docetaxel and pembrolizumab for previously treated patients with metastatic NSCLC and progressive disease after anti-PD-(L)1 inhibitor alone or in combination with platinum-doublet chemotherapy. This study evaluates the efficacy and safety of this triple combination and is being conducted at Peking Union Medical College Hospital in Beijing, China, with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as the principal investigator, with support from Merck. The study enrolled 47 patients. The primary endpoint is investigator-based ORR (RECIST 1.1). The secondary endpoints include PFS, OS, DoR, and safety. The regimen includes pembrolizumab 200 mg IV every three weeks (Q3W) on Day 1, docetaxel 75 mg/m2 IV Q3W on Day 1, and plinabulin 30 mg/m2 IV Q3W on Day 1 in a 21-day cycle. The study is funded by Merck’s Investigator Studies Program and BeyondSpring with provision of study drug and financial support. The study is registered on ClinicalTrials.gov under NCT05599789.
Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com
